Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies

Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies

Introduction: Studies assessing immune responses following Pfizer-BioNTech BNT162b2 mRNA COVID-19 (Pfizer) and ChAdOx1 nCoV-19 AZD1222 (AstraZeneca) vaccines in patients with hemoglobinopathy are non-existent in the literature despite being thought at high risk of infection. Methods: Prospectively,...

Full description

Bibliographic Details
Main Authors: Osman O. Radhwi, Hamza Jan, Abdullah Waheeb, Sawsan S. Alamri, Hatem M. Alahwal, Iuliana Denetiu, Ashgan Almanzlawey, Adel F. Al-Marzouki, Abdullah T. Almohammadi, Salem M. Bahashwan, Ahmed S. Barefah, Mohamad H. Qari, Adel M. Abuzenadah, Anwar M. Hashem
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Vaccines
Subjects:
BNT162b2
ChAdOx1 nCoV-19
COVID-19
vaccine
thalassemia
sickle cell disease
Online Access:https://www.mdpi.com/2076-393X/10/2/151

Internet

https://www.mdpi.com/2076-393X/10/2/151

Similar Items